

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 February 2024 (01.02.2024)



(10) International Publication Number
WO 2024/022602 A1

(51) International Patent Classification:
C07K 14/52 (2006.01) C07K 14/715 (2006.01)
A61K 39/39 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2022/086161

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:
15 December 2022 (15.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2211075.3 28 July 2022 (28.07.2022) GB
2211076.1 28 July 2022 (28.07.2022) GB

(71) Applicant: **AKAMIS BIO LTD** [GB/GB]; AKAMIS
HOUSE, 4-10 The Quadrant, Barton Lane, Abingdon, Ox-
fordshire OX14 3YS (GB).

(72) Inventors: **CHAMPION, Brian**; c/o Psioxus House, 4-10
The Quadrant, Barton Lane, Abingdon Oxfordshire OX14
3YS (GB). **SASSO, Maria Stella**; c/o Psioxus House, 4-10
The Quadrant, Barton Lane, Abingdon Oxfordshire OX14
3YS (GB).

(74) Agent: **STERLING IP**; Orion House, Bessemer Road,
Welwyn Garden City, Hertfordshire AL7 1HH (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: VIRUS ENCODING TRANSGENES TO COMPLEMENT CELLULAR THERAPY

(57) Abstract: An oncolytic group B adenovirus suitable for treating a solid tumour (for example sarcoma, carcinoma and/or lymphoma) comprising a sequence of formula (I): 5'ITR-B1-BA-B2-BX-BB-BY-B3-3'ITR (I) wherein: a first transgene encodes a polypeptide comprising a target-sequence specific for a binding domain on the cells of a cell-based immunotherapy, for example bearing a (exogenous) recombinant surface expressed protein, such as a chimeric antigen receptor or an NKG2D receptor, in particular wherein the target-sequence specifically binds to said surface expressed protein (more especially the chimeric antigen receptor) on the immunotherapy cell; and a second transgene encodes a polypeptide comprising a molecule that promotes trafficking of the cell-based immunotherapy into and within the tumour.



WO 2024/022602 A1